SICEM 2025

Breakfast symposium 1 [Bayer & HK inno.N] Day 3, Saturday, April 13, 07:30-08:00 / Room 1 (1F)

Chairpersons : Kyoil Suh (Soonchunhyang University, Korea), Kang Seo Park (Eulji University, Korea)

	07:30-07:45	The new way to reach novel diabetic kidney disease treatment, finerenone clinical outcomes Mi-Hae Seo (Soonchunhyang University, Korea)
	07:45-08:00	What’s new in type 2 diabetes? Dapagliflozin and sitagliptin combination! Se Eun Park (Sungkyunkwan University, Korea)

Breakfast symposium 2 [Yuhan & Yooyoung] Day 3, Saturday, April 13, 07:30-08:00 / Room 2 (1F)

Chairpersons : Chang Beom Lee (Hanyang University, Korea), Seok Won Park (Yonsei University, Korea)

	07:30-07:45	The metabolic-renal-cardio benefit of SGLT2 inhibitors in type 2 diabetes Yeoree Yang (The Catholic University of Korea, Korea)
	07:45-08:00	New combination : pioglitazone and dapagliflozin Jun Hwa Hong (Eulji university, Korea)

Luncheon symposium 1 [Novo Nordisk & Daewoong Pharmaceutical] Day 2, Friday, April 12, 12:10-12:40 / Room 1,2 (1F)

Chairpersons : Young-Kee Shong (ThanQ Seoul Clinic, Korea), Jihyun Lee (Daegu Catholic University, Korea)

	12:10-12:25	Latest update on patient benefits of switching to IDegLira from other injection therapies Eun Young Lee (The Catholic University of Korea, Korea)
	12:25-12:40	Novel enhanced SGLT2 inhibitor - a pooled analysis Young Sang Lyu (Chosun University, Korea)

Luncheon symposium 2 [Chong Kun Dang Pharm & Amgen] Day 2, Friday, April 12, 12:10--12:40 / Room 3 (B2)

Chairpersons : Sung Koo Kang (The Catholic University of Korea, Korea), Dong Won Byun (Soonchunhyang University, Korea)

	12:10-12:25	The combination of DPP-4 inhibitor plus SGLT2 inhibitor as an attractive treatment option Bo-Yeon Kim (Soonchunhyang University, Korea)
	12:25-12:40	Treatment journey to protect bones from fractures Yunkyung Jeon (Pusan National University, Korea)

Luncheon symposium 3 [BI-LLY & Dong-A ST] Day 2, Friday, April 12, 12:10-12:40 / Room 4 (B2)

Chairpersons : Hyoung Woo Lee (Yeungnam University, Korea), Bon Jeong Ku (Chungnam National University, Korea)

	12:10-12:25	Empagliflozin, expanding horizons for the treatment of CRM Gyuri Kim (Sungkyunkwan University, Korea)
	12:25-12:40	Differentiated metabolic effects of DA-1726, a new GLP-1R/GCGR dual agonist Yuna Chae (Dong-A ST, Korea)

Luncheon symposium 4 [Sanofi & Celltrion] Day 3, Saturday, April 13, 12:50-13:20 / Room (1F)

Chairpersons : Dae Jung Kim (Ajou University, Korea), Jong Chul Won (Inje University, Korea)

	12:50-13:05	Insulin therapy optimization: unlocking the potential for better diabetes treatment Chaiho Jeong (The Catholic University of Korea, Korea)
	13:05-13:20	Reappraisal of TZD to control diabetes: pioglitazone Jang Won Son (The Catholic University of Korea, Korea)

Luncheon symposium 5 [Hanmi Pharmaceutical & Bayer] Day 3, Saturday, April 13, 12:50-13:20 / Room 2 (1F)

Chairpersons : Gwang Won Kim (Gachon University, Korea), Eun Seok Kang (Yonsei University, Korea)

	12:50-13:05	It’s time to break therapeutic inertia in dyslipidemia treatment Sung Hoon Yu (Hanyang University, Korea)
	13:05-13:20	Looking at clinical practice through the lens of finerenone Suk Chon (Kyung Hee University, Korea)

Luncheon symposium 6 [Handok & JW Pharmaceutical] Day 3, Saturday, April 13, 12:50-13:20 / Room 3 (B2)

Chairpersons : In Joo Kim (Kim Yong Ki Internal Medicine Clinic, Korea), Heung Yong Jin (Jeonbuk National University, Korea)

	12:50-13:05	A new look at the classic, Lantus ® in type 2 diabetes So Hun Kim (Inha University, Korea)
	13:05-13:20	Cutting edge care of pitavastatin with ezetimibe combination therapy Jung Hwan Park (Hanyang University, Korea)

Scientific program